Exact claim · Version 1 · Reviewed 2026-07-23
“Bremelanotide is FDA-approved for a specific form of HSDD.”
A verdict on this wording and scope, not a universal grade for Bremelanotide.
01 · Verdict
Supported with scope
Vyleesi is approved for acquired, generalized HSDD in certain premenopausal women after specified exclusions.
- Evidence basis
- Regulatory or product record
- Scope
- The population and limitations in the current Vyleesi label.
- Category
- Approval and status
02 · Primary record
Check the attached evidence
- Editorial review
- Internal editorial review recorded
- Responsible editor
- Anthony Treviso · Founder and responsible editor
- Clinical-review boundary
- Not independently medically reviewed.